ALKS 2680 Dose 1: Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
ALKS 2680 Dose 2: Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
ALKS 2680 Dose 3: Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
Placebo: Participants will receive placebo tablets, daily, orally for 12 weeks
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
| Facility | City | Region | Status |
|---|---|---|---|
| Alkermes Investigational Site | Cullman | Alabama | Recruiting |
| Alkermes Investigational Site | Phoenix | Arizona | Recruiting |
| Alkermes Investigational Site | Los Angeles | California | Recruiting |
| Alkermes Investigational Site | Boulder | Colorado | Recruiting |
| Alkermes Investigational Site | Brandon | Florida | Recruiting |
| Alkermes Investigational Site | Maimi | Florida | Recruiting |
| Alkermes Investigational Site | Winter Park | Florida | Recruiting |
| Alkermes Investigational Site | Macon | Georgia | Recruiting |
| Alkermes Investigational Site | Stockbridge | Georgia | Recruiting |
| Alkermes Investigational Site | Kansas City | Kansas | Recruiting |
| Alkermes Investigational Site | Newton | Massachusetts | Recruiting |
| Alkermes Investigational Site | Lansing | Michigan | Not Yet Recruiting |
| Alkermes Investigational Site | Novi | Michigan | Recruiting |
| Alkermes Investigational Site | Charlotte | North Carolina | Recruiting |
| Alkermes Investigational Site | Huntersville | North Carolina | Recruiting |
| Alkermes Investigational Site | Cincinnati | Ohio | Recruiting |
| Alkermes Investigational Site | Wyomissing | Pennsylvania | Recruiting |
| Alkermes Investigational Site | Columbia | South Carolina | Recruiting |
| Alkermes Investigational Site | Austin | Texas | Recruiting |
| Alkermes Investigational Site | Frisco | Texas | Recruiting |
| Alkermes Investigational Site | San Antonio | Texas | Recruiting |
| Alkermes Investigational Site | Sugar Land | Texas | Recruiting |
| Alkermes Investigational Site | Sydney | New Sout | Recruiting |
| Alkermes Investigational Site | Bruges | Belgium | Recruiting |
| Alkermes Investigational Site | Edegem | Belgium | Recruiting |
| Alkermes Investigational Site | Namur | Belgium | Recruiting |
| Alkermes Investigational Site | Markham | Ontario | Recruiting |
| Alkermes Investigational Site | Toronto | Ontario | Recruiting |
| Alkermes Investigational Site | Bordeaux | France | Recruiting |
| Alkermes Investigational Site | Lyon | France | Recruiting |
| Alkermes Investigational Site | Montpellier | France | Recruiting |
| Alkermes Investigational Site | Bologna | Italy | Recruiting |
| Alkermes Investigational Site | Kitakyushu-shi | Fukuoka | Recruiting |
| Alkermes Investigational Site | Osaka | Osaka | Recruiting |
| Alkermes Investigational Site | Shibuya-ku | Tokyo-To | Recruiting |
| Alkermes Investigational Site | Shinjuku-ku | Tokyo-To | Recruiting |
| Alkermes Investigational Site | Heeze | Netherlands | Recruiting |
| Alkermes Investigational Site | Barcelona | Spain | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07502443 on ClinicalTrials.gov ↗ ← All trials in the USA